Truist Financial Corp Supernus Pharmaceuticals, Inc. Transaction History

Truist Financial Corp

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2023 Aug 01, 2023	SELL	$29.91 - $38.73 $98,762 - $127,886	-3,302 Reduced 13.12%	21,866 $657,000
Q1 2023 May 05, 2023	SELL	$34.93 - $42.03 $11,247 - $13,533	-322 Reduced 1.26%	25,168 $911,000
Q4 2022 Feb 17, 2023	BUY	$31.09 - $37.88 $512,953 - $624,982	16,499 Added 183.51%	25,490 $909,000
Q3 2022 Oct 26, 2022	SELL	$28.79 - $35.41 $256,490 - $315,467	-8,909 Reduced 49.77%	8,991 $304,000
Q2 2022 Jul 22, 2022	SELL	$25.33 - $34.25 $9,524 - $12,878	-376 Reduced 2.06%	17,900 $517,000
Q1 2022 Apr 22, 2022	SELL	$28.51 - $32.9 $23,207 - $26,780	-814 Reduced 4.26%	18,276 $590,000
Q4 2021 Feb 14, 2022	BUY	$26.37 - $34.22 $20,331 - $26,383	771 Added 4.21%	19,090 $557,000
Q3 2021 Nov 05, 2021	BUY	$23.54 - $31.39 $431,229 - $575,033	18,319 New	18,319 $489,000
Q3 2020 Nov 13, 2020	SELL	$20.2 - $25.05 $279,669 - $346,817	-13,845 Closed	0 $0
Q2 2020 Aug 14, 2020	BUY	$17.09 - $24.89 $2,939 - $4,281	172 Added 1.26%	13,845 $329,000
Q1 2020 May 15, 2020	BUY	$14.45 - $24.69 $197,574 - $337,586	13,673 New	13,673 $246,000

282

60.9M

27.7K

11.3K

Ticker SUPN
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—Specialty & Generic
Shares Outstandng 53,495,300
Market Cap $1.93B
Description
Supernus Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of products for the treatment of central nervous system (CNS) diseases in the United States. Its commercial products are Trokendi XR, an extended release topiramate product indicated for the treatment of epilepsy, as well as for the prop...

Get notified when there are updates to the investment portfolio of Truist Financial Corp, based on Form 13F filings with the SEC.

Stay updated on Truist Financial Corp with notifications on news.